Comparison of Allogeneic Hematopoietic Cell Transplantation and Chemotherapy in Elderly Patients with Non-M3 Acute Myelogenous Leukemia in First Complete.

Slides:

Advertisements

Similar presentations

Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation Nirali N. Shah, Michael J. Borowitz,

Advertisements

Decision Analysis of Postremission Therapy in Cytogenetically Intermediate-Risk Acute Myeloid Leukemia: The Impact of FLT3 Internal Tandem Duplication,

Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated.

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.

Intravenous Busulfan-Cyclophosphamide as a Preparative Regimen Before Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Acute.

Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma Taewoong Choi, Murali K. Kodali, Wen-Kai Weng

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI Alix O’Meara, Jörg Halter, Dominik.

Clinical Utility of Wilms' Tumor 1 Monitoring in Patients with Myeloid Malignancy and Prior Allogeneic Hematopoietic Stem Cell Transplantation Kazuko.

Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis Armin Rashidi,

Haploidentical and Matched Sibling Donor Hematopoietic Cell Transplantation for Patients with HLA-Homozygous Haplotypes Junya Kanda, Kazuhiro Ikegame,

Jacob M. Rowe Biology of Blood and Marrow Transplantation

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia Mei-Jie.

Quantifying the Survival Benefit for Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed Acute Myelogenous Leukemia Paul M. Armistead, Marcos.

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Absolute Lymphocyte Count on Day 30 Is a Surrogate for Robust Hematopoietic Recovery and Strongly Predicts Outcome after T Cell-Depleted Allogeneic Stem.

Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation Takashi Tanaka, Yoshihiro Inamoto, Takuya Yamashita,

Favorable Outcome for Infant Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation David A. Jacobsohn, Brad Hewlett, Elaine Morgan,

Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission Jennifer L. Holter.

Comparison of Cord Blood Transplantation with Unrelated Bone Marrow Transplantation in Patients Older than Fifty Years Masatsugu Tanaka, Koichi Miyamura,

Comparison of Autologous and Unrelated Transplants for Cytogenetically Normal Acute Myelogenous Leukemia Motonori Mizutani, Akiyoshi Takami, Masahiko.

Alternative Donor Transplantation for Older Patients with Acute Myeloid Leukemia in First Complete Remission: A Center for International Blood and Marrow.

Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological.

Monosomal Karyotype Provides Better Prognostic Prediction after Allogeneic Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia Betul.

Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation Philippe Armand, Haesook T. Kim, Daniel.

Twenty Years of Unrelated Donor Bone Marrow Transplantation for Pediatric Acute Leukemia Facilitated by the National Marrow Donor Program Margaret L.

Successful Prevention of Acute Graft-versus-Host Disease Using Low-Dose Antithymocyte Globulin after Mismatched, Unrelated, Hematopoietic Stem Cell Transplantation.

Biology of Blood and Marrow Transplantation

Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation Lindsay G. Jensen, Tracey Stiller,

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Donor Lymphocyte Infusion for the Treatment of Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective.

Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.

Fludarabine and 2-Gy TBI is Superior to 2 Gy TBI as Conditioning for HLA-Matched Related Hematopoietic Cell Transplantation: A Phase III Randomized Trial

Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis Nicolas Novitzky, Valda.

Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid.

Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older Koji Kawamura,

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation? Melhem.

Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation Merav Bar, Weigang Tong, Megan Othus,

The Outcome of Allogeneic Hematopoietic Cell Transplantation for Children with FMS- Like Tyrosine Kinase 3 Internal Tandem Duplication–Positive Acute Myelogenous.

Impact of Donor and Recipient Cytomegalovirus Serostatus on Outcomes of Antithymocyte Globulin–Conditioned Hematopoietic Cell Transplantation Amit Kalra,

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Late Mortality and Causes of Death among Long-Term Survivors after Allogeneic Stem Cell Transplantation Yoshiko Atsuta, Akihiro Hirakawa, Hideki Nakasone,

Pretransplantation Therapy with Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients with MDS Aaron T. Gerds, Ted A. Gooley,

Excellent Outcome of Allogeneic Hematopoietic Stem Cell Transplantation Using a Conditioning Regimen with Medium-Dose VP-16, Cyclophosphamide and Total-Body.

Allogeneic Transplantation for Adult Acute Leukemia in First and Second Remission with a Novel Regimen Incorporating Daily Intravenous Busulfan, Fludarabine,

Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated.

Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With.

Cytogenetics Does Not Impact Outcomes in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation Ibrahim.

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia Patients with Central Nervous System Involvement Jun Aoki, Ken.

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Abnormalities of the Short Arm of Chromosome 17 Jinichi.

Improved Outcome for Peripheral Blood Stem Cell Transplantation for Advanced Primary Myelodysplastic Syndrome Scott R. Solomon, Bipin N. Savani, Richard.

Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-

Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents Moreno Festuccia, Kelsey Baker, Theodore.

Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome Bart L. Scott, Barry Storer,

Treosulfan, Fludarabine, and 2-Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome.

Homozygous HLA-C1 is Associated with Reduced Risk of Relapse after HLA-Matched Transplantation in Patients with Myeloid Leukemia Nobuyoshi Arima, Junya.

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse

Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation Nirali N. Shah, Michael J. Borowitz,

Superior Survival of Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Compared with Chemotherapy Alone Used as Post-Remission Therapy.

Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemia–Rearranged Acute Leukemia Who Are at High Risk of.

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Treatment versus Transplant for Challenging Hematologic Disorders

Allogeneic Peripheral Blood Stem Cell Transplantation is a Promising and Safe Choice for the Treatment of Refractory/Relapsed Acute Myelogenous Leukemia,

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Impact of T Cell Chimerism on Clinical Outcome in 117 Patients Who Underwent Allogeneic Stem Cell Transplantation with a Busulfan-Containing Reduced-Intensity.

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Idarubicin-Intensified Hematopoietic Cell Transplantation Improves Relapse and Survival of High-Risk Acute Leukemia Patients with Minimal Residual Disease

Presentation transcript:

Comparison of Allogeneic Hematopoietic Cell Transplantation and Chemotherapy in Elderly Patients with Non-M3 Acute Myelogenous Leukemia in First Complete Remission Saiko Kurosawa, Takuhiro Yamaguchi, Naoyuki Uchida, Shuichi Miyawaki, Kensuke Usuki, Masato Watanabe, Takuya Yamashita, Heiwa Kanamori, Junji Tomiyama, Yuichiro Nawa, Shingo Yano, Jin Takeuchi, Kazuaki Yakushiji, Fumiaki Sano, Nobuhiko Uoshima, Takahiro Yano, Yasuhito Nannya, Yukiyoshi Moriuchi, Ikuo Miura, Yoichi Takaue, Takahiro Fukuda Biology of Blood and Marrow Transplantation Volume 17, Issue 3, Pages 401-411 (March 2011) DOI: 10.1016/j.bbmt.2010.07.013 Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Patient flow. Among 953 patients for whom information was available, HLA typing was performed in 331 patients in CR1 (35%). Related donors were found in 134 patients (40%). Among the patients who had a related donor, 76 (57%) actually underwent allo-HCT in CR1. Among the 197 patients without a related donor, 76 (39%) received allo-HCT from an alternative donor in CR1. Biology of Blood and Marrow Transplantation 2011 17, 401-411DOI: (10.1016/j.bbmt.2010.07.013) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Outcomes according to treatment in CR1 (total elderly patients). Relapse (upper left), nonrelapse mortality (upper right), relapse-free survival (bottom left), and overall survival (OS) (bottom right) of patients who underwent allogeneic hematopoietic cell transplantation in CR1 and those who did not are shown. Forty-six patients who died or relapsed within 60 days from CR1 were excluded as described in the Statistical Analysis. OS was significantly improved in the HCT group (P = .012). Biology of Blood and Marrow Transplantation 2011 17, 401-411DOI: (10.1016/j.bbmt.2010.07.013) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Outcomes according to treatment in CR1 (cytogenetic risks). Relapse (upper left), nonrelapse mortality (upper right), relapse-free survival (bottom left), and overall survival (OS) (bottom right) of patients who underwent allogeneic hematopoietic cell transplantation in CR1 and those who did not are shown among (A) intermediate-risk AML and (B) unfavorable-risk AML. (A) OS was significantly improved in the HCT group among patients with intermediate-risk AML. (B) Relapse incidence was high even after HCT, and OS in the HCT group did not significantly differ from that in the CTx group. Biology of Blood and Marrow Transplantation 2011 17, 401-411DOI: (10.1016/j.bbmt.2010.07.013) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Outcomes according to treatment in CR1 (donor availability). Relapse (upper left), nonrelapse mortality (NRM) (upper right), relapse-free survival (bottom left), and overall survival (OS) (bottom right) of patients who underwent allogeneic hematopoietic cell transplantation in CR1 and those who did not are shown among (A) patients who had a suitable related donor and (B) patients who did not have a suitable related donor. (A) NRM was reduced in related donor transplant and survival probabilities were significantly improved in the HCT group. (B) OS in alternative donor transplant did not significantly differ from that in the CTx group. Biology of Blood and Marrow Transplantation 2011 17, 401-411DOI: (10.1016/j.bbmt.2010.07.013) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Overall survival from CR1 are compared between the patients who received allogeneic transplantation in first complete remission and those who did not among the group of patients who had a suitable related donor. (A) Comparison of the two groups when 622 patients who did not have their HLA typed (those who were not known to have a suitable related donor) were included in the chemotherapy group (66% versus 54%, P = .011). (B) Comparison of the two groups when landmark was extended to 5 months from CR1 (66% versus 54%, P = .068). (C) Comparison of the two groups limited to intermediate-risk AML patients (78% versus 63%, P = .048). Biology of Blood and Marrow Transplantation 2011 17, 401-411DOI: (10.1016/j.bbmt.2010.07.013) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

(A) Overall survival (OS) rates from CR1 are compared between myeloablative and reduced-intensity conditioning regimens. There were no significant differences between myeloablative and reduced-intensity conditioning regimens (63% versus 61%, P = .571). (B) OS did not differ significantly according to the application of total-body irradiation among patients who received myeloablative regimen (TBI regimen versus non-TBI: 67% versus 61%, P = .932). (C) Among patients who received reduced-intensity conditioning regimen, OS from CR1 did not differ significantly among different regimens (fludarabine + busulfan-based, 56%; fludarabine + melphalan-based, 67%; others, 68%, P = .862). Biology of Blood and Marrow Transplantation 2011 17, 401-411DOI: (10.1016/j.bbmt.2010.07.013) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions